Market
Will ErSO-TFPy show effectiveness in treating estrogen receptor-positive breast cancer in human trials by end of 2026?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Results published in peer-reviewed medical journals
Story
New Ultra-Fast Cancer Treatment ErSO-TFPy Promises Less Side Effects and Rapid Results in Less Than a Second
Jan 23, 2025, 03:02 AM
Recent research highlights a groundbreaking ultra-fast cancer treatment that could potentially replace conventional radiotherapy. This innovative approach, referred to as Flash Radiotherapy, promises to address a broader range of cancers while minimizing side effects and significantly reducing treatment time to less than a second. Additionally, a study on the drug candidate ErSO-TFPy has demonstrated its effectiveness in eradicating small breast cancer tumors in mice, indicating potential for treating estrogen receptor-positive breast cancer with minimal side effects. Further testing is required to confirm these findings and assess the treatments' applicability in clinical settings.
View original story
Similar markets
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Successful with moderate results • 25%
Trial not initiated • 25%
Unsuccessful • 25%
Successful with significant results • 25%